As global pharmaceutical players navigate economic headwinds and regulatory shifts, Evaluate’s World Preview 2025 infographic delivers a concise, data-driven snapshot of what lies ahead. From the meteoric rise of GLP-1s to China’s growing influence and the looming patent cliff, this visual guide highlights the forces reshaping the industry through 2030.
Key Highlights:
- GLP-1s surge ahead: With a projected CAGR of 20% through 2030, GLP-1-based therapies are set to account for nearly 9% of all prescription drug sales.
- China’s biotech boom: Chinese-origin assets are expected to make up 40% of all licensing deals in 2025—up from just 3% five years ago.
- Patent pressures mount: Big Pharma faces $300 billion in potential lost sales by 2030, intensifying the focus on multi-indication blockbusters.
Download the infographic now to explore the data shaping tomorrow’s pharma strategies.
